Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeCLINICAL TRIALS, STUDIES, DATALate-Breaking Data Shows the CardioMEMS HF System is Effective in Reducing Heart...

Late-Breaking Data Shows the CardioMEMS HF System is Effective in Reducing Heart Failure Hospitalizations and Cost of Care

Late-breaking featured clinical research presented today adds strong clinical support for Abbott’s CardioMEMS HF System as an effective real-world approach to reduce heart failure hospitalizations and combat the rising cost of heart failure.

The CardioMEMS HF System is the first and only U.S. Food and Drug Administration-approved monitor that, when used by physicians to manage heart failure, has been shown to significantly reduce heart failure hospital admissions and improve the quality of life in patients with heart failure (NYHA Class III). The latest research includes more than 1,100 Medicare patients and was presented today during the American College of Cardiology (ACC) 66th Annual  Scientific Sessions in Washington, D.C., and simultaneously published in the Journal of the American College of Cardiology (JACC).

Researchers found a 46 percent reduction in heart failure hospitalizations in patients six months after receiving the CardioMEMS HF System, and a 34 percent reduction at 12 months post-implant. The data are consistent with what was seen in the CHAMPION clinical trial, further confirming that when physicians adjust medications based on the patient’s pulmonary artery pressures, related hospitalizations are significantly reduced.

“These results support the clinical effectiveness and potential cost savings of using an implantable hemodynamic monitor to help with heart failure management,” said Akshay Desai, M.D., director of the Heart Failure Disease Management Program at Brigham and Women’s Hospital in Boston, Mass. “Reducing heart failure hospitalizations is an important goal for patients and hospitals alike, and may help to improve long-term clinical outcomes and quality of life for our patients.”

The data also showcased important cost-savings captured through reductions in heart failure hospitalizations associated with the use of the CardioMEMS HF System. In particular, in the six months post-implant, each patient had an average reduction of more than $10,500 in comprehensive health care costs compared to the six months prior to implant. Twelve month post-implant analysis showed a $13,190 reduction in costs per patient.

“The reduction in hospitalizations and costs associated with heart failure confirmed by these data shows that proactive patient management with the CardioMEMS HF System is successful in mainstream practice and results in improved clinical outcomes,” said Philip Adamson, M.D., medical director of Abbott’s heart failure business. “Success with this technology for us means helping patients get back to living their life.”

Data were collected using U.S. Medicare claims from patients undergoing a CardioMEMS sensor implant to measure pulmonary artery pressure, and the rates of heart failure hospitalizations from before and after the implant were compared. Comprehensive heart failure-related costs were also compared. The data confirmed that hemodynamic (pulmonary artery pressure) monitoring with the CardioMEMS HF System in an outpatient setting reduced heart failure hospitalization for patients while also reducing related costs.

Additional data on managing heart failure patients with the CardioMEMS HF System published on Feb. 22, 2017, in CirculationImpact of Practice Based Management of PA Pressures in 2,000 Patients Implanted with the CardioMEMS Sensor—showed that patient compliance and physician-directed management outside of a clinical study led to a significant reduction of pulmonary artery pressures.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

HistoSonics Receives FDA “Breakthrough Device Designation” for Novel Sonic Beam Therapy

Histotripsy of the liver provides clinicians the first automated external beam therapy using acoustic energy to mechanically destroy and liquefy tissue in the liver without incisions, ionizing radiation or heat.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Endolumik Inc. of Morgantown Secures $175,000 Angel Investment from Country Roads Angel Network

Endolumik, Inc. was founded in May 2020 by Mara McFadden, chief executive officer, and Dr. Nova Szoka, inventor of the surgical device.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

By using this website you agree to accept Medical Device News Magazine Privacy Policy